Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy

被引:0
作者
Hartrampf, Philipp E. [1 ]
Mihatsch, Patrick W. [2 ]
Seitz, Anna Katharina [3 ]
Solnes, Lilja B. [4 ]
Rowe, Steven P. [4 ]
Pomper, Martin G. [4 ]
Kuebler, Hubert [3 ]
Bley, Thorsten A. [2 ]
Buck, Andreas K. [1 ]
Werner, Rudolf A. [1 ,4 ]
机构
[1] Univ Hosp Wurzburg, Dept Nucl Med, Wurzburg, Germany
[2] Univ Hosp Wurzburg, Dept Diagnost & Intervent Radiol, Wurzburg, Germany
[3] Univ Hosp Wurzburg, Dept Urol & Paediat Urol, Wurzburg, Germany
[4] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Sch Med, Baltimore, MD USA
关键词
PSMA; prostate cancer; radioligand therapy; overall survival; body composition; ANDROGEN-DEPRIVATION THERAPY; CLINICAL-OUTCOMES; OPEN-LABEL; MEN; FAT; CHEMOTHERAPY; MITOXANTRONE; CABAZITAXEL; ABIRATERONE; PREDNISONE;
D O I
10.2967/jnumed.122.265379
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In patients with prostate cancer scheduled for systemic treatment, being overweight is linked to prolonged overall survival (OS), whereas sarcopenia is associated with shorter OS. We investigated fat-related and body composition parameters in patients undergoing prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) to assess their predictive value for OS. Methods: Body mass index (BMI, in kg/m(2)) and CT-derived body composition parameters (total, subcutaneous, visceral fat area, and psoas muscle area at the L3-L4 level) were determined for 171 patients scheduled for PSMA-directed RLT. After normalization for stature, the psoas muscle index was used to define sarcopenia. Outcome analysis was performed using Kaplan-Meier curves and Cox regression including fat-related and other clinical parameters (Gleason score, C-reactive protein [CRP], lactate dehydrogenase [LDH], hemoglobin, and prostate-specific antigen levels). The Harrell C-index was used for goodness-of-fit analysis. Results: Sixty-five patients (38%) had sarcopenia, and 98 patients (57.3%) had increased BMI. Relative to the 8-mo OS in normal-weight men (BMI < 25), overweight men (25 = BMI > 30) and obese men (BMI =30) achieved a longer OS of 14 mo (hazard ratio [HR], 0.63; 95% CI, 0.40-0.99; P = 0.03) and 13 mo (HR, 0.47; 95% CI, 0.29-0.77; P = 0.004), respectively. Sarcopenia showed no impact on OS (11 vs. 12 mo; HR, 1.4; 95% CI, 0.91-2.1; P = 0.09). Most of the body composition parameters were tightly linked to OS on univari-able analyses, with the highest C-index for BMI. In multivariable analy-sis, a higher BMI (HR, 0.91; 95% CI, 0.86-0.97; P = 0.006), lower CRP (HR, 1.09; 95% CI, 1.03-1.14; P < 0.001), lower LDH (HR, 1.08; 95% CI, 1.03-1.14; P < 0.001), and longer interval between initial diagnosis and RLT (HR, 0.95; 95% CI, 0.91-0.99; P = 0.02) were significant pre-dictors of OS. Conclusion: Increased fat reserves assessed by BMI, CRP, LDH, and interval between initial diagnosis and RLT, but not CT-derived body composition parameters, were relevant predictors for OS. As BMI can be altered, future research should investigate whether a high-calorie diet before or during PSMA RLT may improve OS.
引用
收藏
页码:1272 / 1278
页数:7
相关论文
共 45 条
  • [1] High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting
    Antoun, Sami
    Bayar, Amine
    Ileana, Ekatarina
    Laplanche, Agnes
    Fizazi, Karim
    di Palma, Mario
    Escudier, Bernard
    Albiges, Laurence
    Massard, Christophe
    Loriot, Yohann
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (17) : 2570 - 2577
  • [2] Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
  • [3] Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort
    Calais, Jeremie
    Gafita, Andrei
    Eiber, Matthias
    Armstrong, Wesley R.
    Gartmann, Jeannine
    Thin, Pan
    Nguyen, Kathleen
    Lok, Vincent
    Gosa, Laura
    Grogan, Tristan
    Esfandiari, Rouzbeh
    Allen-Auerbach, Martin
    Quon, Andrew
    Bahri, Shadfar
    Gupta, Pawan
    Gardner, Linda
    Ranganathan, David
    Slavik, Roger
    Dahlbom, Magnus
    Herrmann, Ken
    Delpassand, Ebrahim
    Fendler, Wolfgang P.
    Czernin, Johannes
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (10) : 1440 - 1446
  • [4] The Akaike information criterion: Background, derivation, properties, application, interpretation, and refinements
    Cavanaugh, Joseph E.
    Neath, Andrew A.
    [J]. WILEY INTERDISCIPLINARY REVIEWS-COMPUTATIONAL STATISTICS, 2019, 11 (03)
  • [5] Nutritional Status and Health-Related Quality of Life in Men with Advanced Castrate-Resistant Prostate Cancer
    Cavka, Luka
    Perme, Maja Pohar
    Zakotnik, Branko
    Kozjek, Nada Rotovnik
    Seruga, Bostjan
    [J]. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2022, 74 (02): : 472 - 481
  • [6] Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer: a systematic review
    Chen, Wen-Jun
    Kong, Da-Ming
    Li, Liang
    [J]. ASIAN JOURNAL OF ANDROLOGY, 2021, 23 (02) : 163 - 169
  • [7] Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel
    Cushen, Samantha J.
    Power, Derek G.
    Murphy, Kevin P.
    McDermott, Ray
    Griffin, Brendan T.
    Lim, Marvin
    Daly, Louise
    MacEneaney, Peter
    Sullivan, Kathleen O'
    Prado, Carla M.
    Ryan, Aoife M.
    [J]. CLINICAL NUTRITION ESPEN, 2016, 13 : E39 - E45
  • [8] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    de Bono, Johann Sebastian
    Oudard, Stephane
    Ozguroglu, Mustafa
    Hansen, Steinbjorn
    Machiels, Jean-Pascal
    Kocak, Ivo
    Gravis, Gwenaelle
    Bodrogi, Istvan
    Mackenzie, Mary J.
    Shen, Liji
    Roessner, Martin
    Gupta, Sunil
    Sartor, A. Oliver
    [J]. LANCET, 2010, 376 (9747) : 1147 - 1154
  • [9] Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
    Feuerecker, Benedikt
    Chantadisai, Maythinee
    Allmann, Anne
    Tauber, Robert
    Allmann, Jakob
    Steinhelfer, Lisa
    Rauscher, Isabel
    Wurzer, Alexander
    Wester, Hans-Juergen
    Weber, Wolfgang A.
    d'Alessandria, Calogero
    Eiber, Matthias
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (06) : 833 - 839
  • [10] Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
    Gafita, Andrei
    Calais, Jeremie
    Grogan, Tristan R.
    Hadaschik, Boris
    Wang, Hui
    Weber, Manuel
    Sandhu, Shahneen
    Kratochwil, Clemens
    Esfandiari, Rouzbeh
    Tauber, Robert
    Zeldin, Anna
    Rathke, Hendrik
    Armstrong, Wesley R.
    Robertson, Andrew
    Thin, Pan
    D'Alessandria, Calogero
    Rettig, Matthew B.
    Delpassand, Ebrahim S.
    Haberkorn, Uwe
    Elashoff, David
    Herrmann, Ken
    Czernin, Johannes
    Hofman, Michael S.
    Fendler, Wolfgang P.
    Eiber, Matthias
    [J]. LANCET ONCOLOGY, 2021, 22 (08) : 1115 - 1125